Inquirer News

FDA: 3rd hospital secures compassionate special permit to use Ivermectin vs COVID-19

Ivermectin has effect vs COVID

A health worker shows a box containing a bottle of Ivermectin, a medicine authorized by the National Institute for Food and Drug Surveillance (INVIMA) to treat patients with mild, asymptomatic or suspicious COVID-19, as part of a study of the Center for Paediatric Infectious Diseases Studies, in Cali, Colombia, on July 21, 2020. (Photo by Luis ROBAYO / AFP)

MANILA, Philippines — Another hospital has been granted a compassionate special permit (CSP) for Ivermectin use against COVID-19, Food and Drug Administration (FDA) Director-General Eric Domingo said Thursday.

Domingo announced this during the hearing of the House committee of good government and public accountability. So far, this is the third hospital in the country to secure a CSP for Uvermectin use against the new coronavirus disease.

However, similar to the first two CSP approvals, Domingo did not disclose the name of the hospital.

“Sa ngayon po mayroon pa pong na-approve na isang hospital kahapon,” Domingo said.

“May pending pa po na isa daw na nag-apply din kahapon na may kulang lang na papel na isu-submit,” he added.

A doctor or a hospital can apply for a CSP when the medicine they want to use is not available or approved here, but registered overseas, Domingo earlier explained.

The FDA, however, stressed that a CSP for any medicine is neither registration of nor a permit to market a drug.

KGA
Exit mobile version